NFE2L2 and cancer: Since survival analysis by cancer type revealed that NSCLC patients with NFE2L2 MU had a poorer OS (Additional file 1: Fig. S3L), but not NFE2L2 mutated NSCLC patients treated with ICIs (Fig. 5F), we used TCGA NSCLC transcriptomic data to assess signal pathway alterations between NFE2L2 MU and NFE2L2 WT groups.